Financing the Future of Individualized Medicine: Funding Models for Rare Genetic Therapies

August 19th, 2025|Categories: Past Webinars|

Date: September 18, 2025 Time: 11-12pm EDT / 5-6pm CEST Title:Financing the Future of Individualized Medicine: Funding Models for Rare Genetic Therapies Description: Individualized medicine has emerged as an approach offering bespoke therapeutics to patients with rare genetic conditions. In spite ...

From Discovery to Deals: The Neurological Oligonucleotide Landscape at a Glance

August 19th, 2025|Categories: Past Webinars|

Date: September 4, 2025 Time: 11-12pm EDT / 5-6pm CEST Title: From Discovery to Deals: The Neurological Oligonucleotide Landscape at a Glance Description: A deep dive on the drug landscape, displaying critical data-driven therapeutic and clinical trial highlights, as well as ...

Strategic IP for Oligonucleotide Therapeutics: Maximizing Innovation Value

July 29th, 2025|Categories: Past Webinars|

Date: August 28, 2025 Time: 11-12pm EDT / 5-6pm CEST Title: Strategic IP for Oligonucleotide Therapeutics: Maximizing Innovation Value Description: This talk will explore the essential elements of an effective IP strategy tailored for oligonucleotide therapeutics, balancing scientific innovation with commercial ...

The importance of involving patients in therapy development; Lessons learned from Duchenne exon skipping

July 29th, 2025|Categories: Past Webinars|

Date: August 21, 2025 Time: 11-12pm EDT / 5-6pm CEST Title: The importance of involving patients in therapy development; Lessons learned from Duchenne exon skipping Description: Duchenne muscular dystrophy is a progressive muscle wasting disease caused by lack of dystrophin protein. ...

Perspectives on Oligonucleotide Therapeutics: A discussion with Rebecca Miles, incoming president of OTS

May 9th, 2025|Categories: Past Webinars|

Date: June 12, 2025 Time: 11-12pm EDT / 5-6pm CEST Title: Perspectives on Oligonucleotide Therapeutics: A discussion with Rebecca Miles, incoming president of OTS Presentation Description: In this interview, Dr. Rebecca Miles, the president-elect of the Oligonucleotide Therapeutics Society, will discuss ...

Go to Top